EUCTR2015-004222-34-ES进行中（未招募）1 期
A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 146
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients age = 18 years of age at the time of informed consent
- •2. Ability to provide and understand written informed consent prior to any study procedures
- •3. Histologically or cytologically confirmed diagnosis of metastatic UM
- •4. Surgically sterile patients or patients of child-bearing potential who agree to use highly effective
- •methods of contraception during study dosing and for 6 months after last dose of study drug
- •5. Life expectancy of > 3 months as estimated by the investigator
- •6. HLA-A*0201 positive by central assay
- •7. ECOG Performance Status of 0 or 1 at Screening
- •8. Patients must have disease (measurable or non-measurable acceptable) according to RECIST v.1.1
- •criteria in Phase I dose escalation cohorts. Patients must have measurable disease in the Phase II
- •dose expansion cohorts
- •9. Phase I dose escalation cohorts only: any prior therapy is acceptable
- •10. Prior therapy in Phase II expansion cohorts:
- •Cohort A: Patients will have experienced disease progression with 1 systemic treatment
- •regimen containing a checkpoint inhibitor, including either a CTLA4 inhibitor (ipilimumab or
- •tremelimumab) and/or a PD-1/PD-L1 inhibitor. Any prior LDT is acceptable in this cohort
- •Cohort B: Patients will have experienced disease progression with 1 or 2 prior lines of therapy,
- •including up to 1 prior line of LDT. LDT will be considered a line of therapy for enrolling this
- •cohort. Prior checkpoint inhibitor therapy is acceptable but not required in this cohort
- •11. All other relevant medical conditions must be well-managed and stable, in the opinion of the
- •investigator, for at least 28 days prior to first administration of study drug
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 125
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 125
排除标准
- •Patients eligible for this study must not meet any of the following criteria:
- •1. Presence of symptomatic or untreated central nervous system (CNS) metastases, or CNS metastases that require doses of corticosteroids within the prior 3 weeks to Study Day 1. Asymptomatic and adequately treated CNS metastases are not exclusionary
- •2. History of severe hypersensitivity reactions to other biologic drugs or monoclonal antibodies
- •3. Patient with any out-of-range laboratory values
- •4. Dose escalation only: Presence of high tumor burden, defined as liver replacement of >60% hepatic organ volume with tumor.
- •5. Clinically significant cardiac disease or impaired cardiac function, including any of the following:
- •Clinically significant and/or uncontrolled heart disease such as congestive heart failure (New York Heart Association grade =2), uncontrolled hypertension or clinically significant arrhythmia currently requiring medical treatment
- •QTcF >470 msec on screening ECG or congenital long QT syndrome
- •Acute myocardial infarction or unstable angina pectoris < 6 months prior to Screening
- •6. Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy before Screening
- •7. Known history of HIV infection. Testing for HIV status is not necessary unless clinically indicated
- •8. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection per institutional protocol. Testing for HBV or HCV status is not necessary unless clinically indicated or the patient has a history of HBV or HCV infection
- •9. Patients receiving systemic treatment with systemic steroid therapy or any other immunosuppressive medication at any dose level that would interfere with the action of the study drugs in the opinion of the investigator
- •10. Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and have not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers; any malignancy considered to be indolent and that has never required therapy; and completely resected carcinoma in situ of any type
- •11. Any medical condition that would, in the investigator’s judgment, prevent the patient’s participation in the clinical study due to safety concerns, compliance with clinical study procedures or interpretation of study results
- •12. Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For cytotoxic or immunotherapy agents that can present with major delayed toxicity (eg, anti-CTLA-4), 4 weeks is indicated as washout period
- •13. Presence of NCI CTCAE = grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if = NCI CTCAE grade 3 and hypothyroidism adequately managed with replacement therapy) due to prior cancer therapy
- •14.Patients with adrenal insufficiency or patients currently requiring chronic, systemic corticosteroid therapy at any dose for longer than 2 weeks. Local steroid therapies (eg, otic, ophthalmic, intraarticular, or inhaled medications) are acceptable.
- •15. Major surgery within 2 weeks of the first dose of study drug (minimally invasive procedures such as bronchoscopy, tumor biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary)
- •16. Radiotherapy within 2 weeks of the first dose of study drug,
研究者
相似试验
进行中（未招募）
1 期
An open-label study in patients with advanced cancer.HLA-A*0201 positive patients with advanced antigen-positive cancer with a histologic diagnosis of Non small cell lung carcinoma (NSCLC), melanoma, urothelial carcinoma, or synovial sarcoma with antigen positivity for NY-ESO-1 and/or LAGE-1AMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: LLTClassification code 10025665Term: Malignant melanoma of skin stage unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10042863Term: Synovial sarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002243-15-GBImmunocore Ltd.63
进行中（未招募）
1 期
Eine offene, multizentrische Phase Ib/II Studie mit 4SC-202 in Kombination mit Pembrolizumab bei Patienten mit einem Melanom der Haut im nicht-resezierbaren Stadium III oder metastasierten Stadium IV, primär refraktär oder ohne Ansprechen auf eine vorherige Behandlung mit einem Anti-PD-1 Antikörper.EUCTR2017-001050-33-DE4SC AG40
进行中（未招募）
1 期
4SC-202 in Combination with Pembrolizumab in Patients with Cutaneous Melanoma - The SENSITIZE Studynresectable Stage III/Metastatic Stage IV CutaneousMelanomaMedDRA version: 20.0Level: LLTClassification code 10027152Term: Melanoma of skin (malignant)System Organ Class: 100000004864EUCTR2017-001050-33-IT4SC AG40
进行中（未招募）
1 期
Study of ART6043 in Advanced/?Metastatic Solid Tumors PatientsCTIS2023-509220-17-00Artios Pharma Limited120
进行中（未招募）
1 期
A study to investigate the use of the study drug NKTR-214 in combination with other approved treatments for solid tumours.EUCTR2016-003543-11-BEektar Therapeutics1,145